Investments
8Portfolio Exits
8Partners & Customers
2About Dompe Farmaceutici
Dompe Farmaceutici is engaged in the development and distribution of ethical drugs and self-medication, adjuvants, medical devices, and cosmetics. It also specializes in the fields of vitamins and mineral supplements and personal hygiene. It is based in Milan, Italy.
Dompe Farmaceutici Headquarter Location
via Santa Lucia, 6
Milan, 20122,
Italy
+39 02583381
Dompe Farmaceutici Web Traffic
Dompe Farmaceutici Rank
Latest Dompe Farmaceutici News
Sep 6, 2018
Hiren September 6, 2018 3 minutes read The global “ High Affinity Nerve Growth Factor Receptor market ” report provides a penetrating analysis of the High Affinity Nerve Growth Factor Receptor market. The report offers a concise outline of the market and describes the main terminologies of the market. The report has enclosed few of the prominent players in the global High Affinity Nerve Growth Factor Receptor market along with their share in the market to evaluate their development during the forecast duration. In this report, the global High Affinity Nerve Growth Factor Receptor market is valued at USD XX million in 2018 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2018 and 2025. The leading market players are Array BioPharma Inc, Astellas Pharma Inc, AstraZeneca Plc, Daiichi Sankyo Co Ltd, Dompe Farmaceutici SpA, Genzyme Corp, Handok Inc, Ignyta Inc, Loxo Oncology Inc, Merck & Co Inc, Nerviano Medical Sciences Srl, Plexxikon Inc, Proximagen Ltd, Rottapharm Bio. The report also takes into account the latest enhancements while foretelling the expansion of the key players. Get Free Sample Copy Here @: http://www.marketresearchstore.com/report/global-high-affinity-nerve-growth-factor-receptor-market-279512#RequestSample The report also evaluates the High Affinity Nerve Growth Factor Receptor market size in the last few years. The study evaluates the global High Affinity Nerve Growth Factor Receptor market in terms of revenue [USD Million] and volume [k MT]. Further, the report also embraces the key restraints and drivers influencing the market growth as well as finds out the evaluation of the market for the forecast period. The report also entails the rising trends coupled with the major avenues for the growth of the High Affinity Nerve Growth Factor Receptor market. Furthermore, the main product type and segments and the sub-segments of the High Affinity Nerve Growth Factor Receptor market are depicted in the report. This brief summary involves business overview, most recent events, product offering, revenue share, strategies, and service offering of the dominant players. Moreover, the complete value chain of the market is also presented in the report coupled with the analysis of the downstream and upstream elements of the market. The global High Affinity Nerve Growth Factor Receptor market is classified based on the types of product and the end-user application segments. The market analysis determines the growth of every segment of the High Affinity Nerve Growth Factor Receptor market mentioned in the report. The data presented in the report is a compilation from diverse industry bodies to estimate the development of the segments in the coming period. Read full Research Report Study at @: http://www.marketresearchstore.com/report/global-high-affinity-nerve-growth-factor-receptor-market-279512 The report also assesses the market growth across major regional segments. The global High Affinity Nerve Growth Factor Receptor market is classified on the basis of geography as Europe, Asia Pacific, Latin America, North America, and Middle East & Africa. Apart from this, the report also covers the competitive scenario existing in the global High Affinity Nerve Growth Factor Receptor market. There are 15 Chapters to display the Global High Affinity Nerve Growth Factor Receptor market Chapter 1, Definition, Specifications and Classification of High Affinity Nerve Growth Factor Receptor , Applications of High Affinity Nerve Growth Factor Receptor , Market Segment by Regions; Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure; Chapter 3, Technical Data and Manufacturing Plants Analysis of High Affinity Nerve Growth Factor Receptor , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis; Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment); Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, High Affinity Nerve Growth Factor Receptor Segment Market Analysis (by Type); Chapter 7 and 8, The High Affinity Nerve Growth Factor Receptor Segment Market Analysis (by Application) Major Manufacturers Analysis of High Affinity Nerve Growth Factor Receptor ; Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type, Market Trend by Application; Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis; Chapter 11, The Consumers Analysis of Global High Affinity Nerve Growth Factor Receptor ; Chapter 12, High Affinity Nerve Growth Factor Receptor Research Findings and Conclusion, Appendix, methodology and data source; Chapter 13, 14 and 15, High Affinity Nerve Growth Factor Receptor sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source. Enquire Here Get customization & check discount for report @: http://www.marketresearchstore.com/report/global-high-affinity-nerve-growth-factor-receptor-market-279512#InquiryForBuying Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, South America, Middle East & Africa. Post Views: 1
Dompe Farmaceutici Investments
8 Investments
Dompe Farmaceutici has made 8 investments. Their latest investment was in Engitix as part of their Series A - II on January 1, 2022.
Dompe Farmaceutici Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
1/19/2022 | Series A - II | Engitix | $54M | Yes | 11 | |
4/10/2020 | Series C | |||||
12/18/2019 | Corporate Minority | |||||
7/25/2016 | Corporate Minority | |||||
1/17/2012 | Corporate Minority |
Date | 1/19/2022 | 4/10/2020 | 12/18/2019 | 7/25/2016 | 1/17/2012 |
---|---|---|---|---|---|
Round | Series A - II | Series C | Corporate Minority | Corporate Minority | Corporate Minority |
Company | Engitix | ||||
Amount | $54M | ||||
New? | Yes | ||||
Co-Investors | |||||
Sources | 11 |
Dompe Farmaceutici Portfolio Exits
8 Portfolio Exits
Dompe Farmaceutici has 8 portfolio exits. Their latest portfolio exit was Dompe Farmaceutici - Rigentex on November 25, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
11/25/2021 | Divestiture | 1 | |||
Date | 11/25/2021 | ||||
---|---|---|---|---|---|
Exit | Divestiture | ||||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 1 |
Dompe Farmaceutici Acquisitions
1 Acquisition
Dompe Farmaceutici acquired 1 company. Their latest acquisition was Anabasis on February 29, 2012.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
2/29/2012 | Other | Acquired |
Date | 2/29/2012 |
---|---|
Investment Stage | Other |
Companies | |
Valuation | |
Total Funding | |
Note | Acquired |
Sources |
Dompe Farmaceutici Partners & Customers
2 Partners and customers
Dompe Farmaceutici has 2 strategic partners and customers. Dompe Farmaceutici recently partnered with Engitix on January 1, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
1/19/2022 | Partner | United Kingdom | Dr Giuseppe Mazza co-founder and CEO of Engitix Ltd said , `` This financing and new partnership with Dompé farmaceutici S.P.A enables us to continue our evolution from a platform to multi-asset mutli-programmes pre-clinical stage company and to continue to prove the value of our human ECM platform . | 2 | |
7/30/2020 | Licensee |
Date | 1/19/2022 | 7/30/2020 |
---|---|---|
Type | Partner | Licensee |
Business Partner | ||
Country | United Kingdom | |
News Snippet | Dr Giuseppe Mazza co-founder and CEO of Engitix Ltd said , `` This financing and new partnership with Dompé farmaceutici S.P.A enables us to continue our evolution from a platform to multi-asset mutli-programmes pre-clinical stage company and to continue to prove the value of our human ECM platform . | |
Sources | 2 |
Dompe Farmaceutici Team
6 Team Members
Dompe Farmaceutici has 6 team members, including current Chief Executive Officer, Nathalie Dompé.
Name | Work History | Title | Status |
---|---|---|---|
Nathalie Dompé | Chief Executive Officer | Current | |
Sergio Dompé | President | Current | |
Giuseppe Andreano | Chief Financial Officer | Current | |
Eriona Gjinukaj | Bain & Company, and Siemens | Chief Operating Officer | Current |
Davide Polimeni | Chief Commercial Officer | Current |
Name | Nathalie Dompé | Sergio Dompé | Giuseppe Andreano | Eriona Gjinukaj | Davide Polimeni |
---|---|---|---|---|---|
Work History | Bain & Company, and Siemens | ||||
Title | Chief Executive Officer | President | Chief Financial Officer | Chief Operating Officer | Chief Commercial Officer |
Status | Current | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.